Reviva Pharmaceuticals Holdings, Inc. Share Price & Technical Analysis
RVPH · $0.39 (-7.14%)
Healthcare / Biotechnology
$0.39
-7.14%
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, su…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
-56% return in May, -20% avg return in past 3 year May month.
-148% return in 2026, -41% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 4% | -25% | -84% | 13% | -56% | – | – | – | – | – | – | – | -148% |
| 25 | 6% | -23% | -34% | -5% | 9% | -58% | 22% | -2% | -18% | 62% | -10% | -51% | -102% |
| 24 | -23% | -1% | 1% | -18% | -56% | -7% | -8% | -4% | 26% | -24% | 8% | 46% | -60% |
| 23 | 12% | -4% | -11% | 63% | -13% | -5% | -20% | -18% | 24% | -2% | -17% | 29% | 39% |
| 22 | -42% | 10% | 27% | -12% | -15% | -37% | -44% | 313% | -25% | 148% | -12% | 17% | 329% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Oversold
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis. It also engages in the clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis. In addition, the company is in preclinical development for the treatment of psoriasis; and RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$10.14M
P/E ratio
—
52W high
$23.20
52W low
$0.26
Volume
72,302
Beta
0.75
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Reviva Pharmaceuticals Holdings, Inc. share price today?
- Reviva Pharmaceuticals Holdings, Inc. (RVPH) last traded around $0.39 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does RVPH have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for RVPH. Download the app for real-time alerts.
- How can I analyze Reviva Pharmaceuticals Holdings, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.